Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A